DKK1 and osteoporosis: Despite the noted effectiveness of DKK-1 inhibitors in osteoporosis, concerns have been raised regarding the increased risk of malignancies due to increased Wnt signaling pathway activation; thus, their safety and efficacy in humans remain to be established [75].